Bristol Myers Squibb Co (NYSE: CELG-RI)

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines that help patients prevail over serious diseases. The company operates as a biopharmaceutical firm focused on transformational therapies in oncology, hematology, immunology, cardiovascular, neuroscience and other therapeutic areas where it aims to create long-term value.

Bristol-Myers Squibb generates revenue primarily through the sale of its portfolio of innovative medicines across multiple therapeutic areas. Key products include Opdivo, Yervoy, Orencia, Reblozyl, Breyanzi, Opdualag, Camzyos, Zeposia, Abecma, Sotyktu, Krazati, Cobenfy, Eliquis, Revlimid, Pomalyst, Sprycel and Abraxane. These medicines are sold worldwide to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, government agencies and, to a lesser extent, directly to patients.

The company operates through a single segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines.

• The single segment encompasses all activities related to the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines that help patients prevail over serious diseases.

Bristol-Myers Squibb competes with other global research-based drug companies, smaller research companies with limited therapeutic focus and generic drug manufacturers. The company leverages its scale, resources and capability as a large pharmaceutical firm combined with the speed, agility and innovation focus typical of the biotech industry to maintain a competitive advantage in developing transformational medicines.

Bristol-Myers Squibb serves wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, government agencies and patients.